FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
News|Videos|November 5, 2020
Pharmacotherapy for Obesity Should Begin in Primary Care
Author(s)Grace Halsey
Video: Obesity expert Dr Louis Aronne outlines the role of medication in obesity treatment and says primary care is absolutely the place to begin.
Advertisement
Louis J Aronne, MD
Director of the Comprehensive Weight Control Center, the Sanford I. Weill Professor of Metabolic Research, Professor of Clinical Medicine at Weill Cornell Medicine
Resources
Intellihealth
Baer HJ, Rozenblum R, De La Cruz BA, et al. Effect of an online weight management program integrated with population health management on weight change . JAMA. 2020;324:1737-1746. doi:10.1001/jama.2020.18977
Advertisement
Related to this article
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
5 FDA Decisions for Primary Care to Know from September 2026
5